Kat6 targeting compounds

A compound of Formula (I):

• or a pharmaceutically acceptable salt or solvate thereof,
• wherein Y-PTM is a moiety of Formula IA:
• wherein
• Y is a covalent bond, or chemical moiety that links PTM and ULM;
• * is a point of attachment to ULM;
• Ring A is a C6-C10 membered aryl group or a 5-10 membered heteroaryl group;
• R1 is H or 5-6 membered heteroaryl optionally substituted by methyl;
• R2 is H, C1-4alk-O—C1-4alkyl, or —(C(R8)2)n-(5-9 membered heteroaryl) optionally substituted by halogen, C1-C3 alkyl, —CH2OH, or —OH;
• R3 is H, halogen, C1-C4 alkyl, cyclopropyl, haloalkyl, C1-C4 alkoxy, or haloalkoxy;
• R4 is H, halogen, C1-C4 alkyl, cyclopropyl, C1-C4 alkoxy, or —O-cyclopropyl;
• each R5 is independently H, halogen, oxo, —OH, —CN, —NO2, —C1-C6alkyl, —C2-C6alkenyl, —C2-C6alkynyl, C0-C1alk-aryl, C0-C1alk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, —ORa, —SRa, —NRcRd, —NRaRc, —C(O)Rb, —OC(O)Ra, —C(O)ORa, —C(O)NRcRd, —S(O)Rb, —S(O)2NRcRd, —S(O)(═NRb)Rb, —SF5, —P(O)RbRb, —P(O)(ORb)(ORb), —B(ORd)(ORc), or —S(O)2Rb;
• each Ra is independently H, —C(O)Rb, —C(O)ORc, —C(O)NRcRd, —C(═NRb)NRbRc, —C(═NORb)NRbRc, —C(═NCN)NRbRc, —P(ORc)2, —P(O)RcRb, —P(O)ORcORb, —S(O)Rb, —S(O)NRcRd, —S(O)2Rb, —S(O)2NRcRd, SiR3, —C1-C10alkyl, —C1-C10 haloalkyl, —C2-C10 alkenyl, —C2-C10 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;
• each Rb is independently H, —C1-C6 alkyl, —C1-C6 haloalkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl;
• each Rc or Rd is independently H, —C1-C10 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —OC1-C6alkyl, —O-cycloalkyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl;
• or
• Rc and Rd, together with the atom to which they are both attached, form a monocyclic or multicyclic heterocycloalkyl, or a monocyclic or multicyclic heterocyclo-alkenyl group;
• each R8 is independently H, halogen, or C1-C4 alkyl;
• m is 0, 1, 2, 3, or 4;
• n is 0 or 1;
• and
• ULM is
• wherein
• is a point of attachment to Y;
• each X2 is independently N or CR15;
• and
• each R15 is independently H, D, halogen, oxo, —OH, —CN, —NO2, —C1-C6alkyl, —C1-C6 haloalkyl, —C2-C6alkenyl, —C2-C6alkynyl, C0-C1alk-aryl, C0-C1alk-heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl, —ORa, —SRa, —NRcRd, —NRaRc, —C(O)Rb, —OC(O)Ra, —C(O)ORa, —C(O)NRcRd, —S(O)Rb, —S(O)2NRcRd, —S(O)(═NRb)Rb, —SF5, —P(O)RbRb, —P(O)(ORb)(ORb), —B(ORd)(ORc) or —S(O)2Rb;
• wherein any of the —C1-C6alkyl, C1-C8 alkoxide, —C2-C6alkenyl, —C2-C6alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, spirocycloalkyl, spiroheterocycloalkyl and spiroheterocycloalkenyl groups in any of R1—R5, R8, R15, and ring Ais optionally substituted by 1-6 Rf groups;
• and
• each R15 independently D, oxo, halogen, C1-C8 alkoxy, C1-C8 alkyl, C1-6 haloalkyl, C1-6 haloalkoxy, —OH, —CN, —NO2, —C2-6 alkenyl, —C2-6 alkynyl, C6-10 aryl, C5-12 heteroaryl, C3-8 cycloalkyl, C3-8 cycloalkenyl, C3-8 heterocycloalkyl, C3-8 heterocycloalkenyl, —ORa, —SRa, —NRcRd, —NRaRc, —C(O)Rb, —OC(O)Rb, —C(O)ORb, —C(O)NRcRd, —S(O)Rb, —S(O)2NRcRd, —S(O)(═NRb)Rb, —SF5, —P(O)RbRb, —P(O)RcRd, —P(O)(ORb)(ORb), —B(ORc)(ORd), —S(O)2Rb, —C(O)NRbORb, —S(O)2ORb, —OS(O)2ORb, or —OPO(ORb)(ORb);
• wherein said C1-C8 alkyl is optionally substituted by 1-6 groups selected from D, halogen, —OH, —CN, —ORa, —SRa, —NRaRd, or NRcRd.